Evidence map›Paper›PMID 36699022›Full record

ArticleFrontiers in endocrinology2022

Structural homology between 11 beta-hydroxysteroid dehydrogenase and

Israel Hernández-Bustamante, Yanina Santander-Plantamura, Dulce Mata-Espinosa, Andrés Reyes-Chaparro, Estela I Bini, Iván Torre-Villalvazo, Armando R Tovar, Jorge Barrios-Payan, Brenda Marquina-Castillo, Rogelio Hernández-Pando and 1 more

Open access · goldAbstract read
In one paragraph

Article in Frontiers in endocrinology, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
1.8field-weighted citation impact, top 14% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 3 citations in OpenAlex.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 3 institutions in 2 countries.

Israel Hernández-BustamanteSección de Patología Experimental, Departamento de Patología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.
Yanina Santander-PlantamuraDepartamento de Farmacología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Dulce Mata-EspinosaSección de Patología Experimental, Departamento de Patología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.
Andrés Reyes-ChaparroDepartamento de Toxicología, Centro de Investigación y de Estudios Avanzados del Instituto Politécnico Nacional (Cinvestav-IPN), Mexico City, Mexico.
Estela I BiniSección de Patología Experimental, Departamento de Patología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.
Iván Torre-VillalvazoDepartamento de Fisiología de la Nutrición, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.
Armando R TovarDepartamento de Fisiología de la Nutrición, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.
Jorge Barrios-PayanSección de Patología Experimental, Departamento de Patología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.
Brenda Marquina-CastilloSección de Patología Experimental, Departamento de Patología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.
Rogelio Hernández-PandoSección de Patología Experimental, Departamento de Patología, Instituto Nacional de Ciencias Médicas y Nutrición "Salvador Zubirán", Mexico City, Mexico.
Andrea CarranzaDepartamento de Farmacología, Facultad de Farmacia y Bioquímica, Universidad de Buenos Aires, Buenos Aires, Argentina.
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán · MXUniversity of Buenos Aires · ARInstituto Politécnico Nacional · MX

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metabolic syndrome is considered the precursor of type 2 diabetes mellitus. Tuberculosis is a leading infection that constitutes a global threat remaining a major cause of morbi-mortality in developing countries. People with type 2 diabetes mellitus are more likely to suffer from infection with

Indexed as

Anti-Infective AgentsDiabetes Mellitus, Type 2Metabolic SyndromeMycobacterium tuberculosisTuberculosis11-beta-Hydroxysteroid Dehydrogenase Type 1AnimalsComorbidityCytokinesDehydroepiandrosteroneGlucocorticoidsHumansMice11-beta-Hydroxysteroid Dehydrogenase Type 1Anti-Infective AgentsCytokinesDehydroepiandrosteroneGlucocorticoids11β-hydroxysteroid dehydrogenasedehydroepiandrosteroneglucocorticoidinflammationInhAlungtuberculosistype 2 diabetes mellitus

Identifiers

PMID36699022
PMCPMC9870073
OpenAlexW4313826441

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.